Previous Close | 48.58 |
Open | 48.84 |
Bid | 49.05 x 800 |
Ask | 49.13 x 1400 |
Day's Range | 48.73 - 49.44 |
52 Week Range | 40.94 - 61.71 |
Volume | |
Avg. Volume | 20,234,166 |
Market Cap | 275.847B |
Beta (5Y Monthly) | 0.62 |
PE Ratio (TTM) | 9.69 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 1.60 (3.25%) |
Ex-Dividend Date | Jul 28, 2022 |
1y Target Est | N/A |
NEW YORK, August 19, 2022--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Mikael Dolsten, Chief Scientific Officer, President, Worldwide Research, Development and Medical, at the Handelsbanken Life Science Innovation Day 2022 on Wednesday, August 24, 2022 at 4:30 p.m. CEST (10:30 a.m. EDT).
NEW YORK, August 12, 2022--Pfizer Inc. (NYSE:PFE) today announced positive top-line results from its pivotal U.S. Phase 3 study (NCT04382326) in infants evaluating its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD) caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes contained in the vaccine for the pediatric population.
NEW YORK & SAINT-HERBLAIN, France, August 08, 2022--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced the initiation of a Phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NCT05477524), to investigate the efficacy, safety and immunogenicity of their investigational Lyme disease vaccine candidate, VLA15.